Nuvation Bio Inc
For the period ended Jun 30, 2024. Filed Aug 5, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 5, 2024
NUVB$4.20-3.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity
(Unaudited, In thousands, except share data)
For the Three and Six Months Ended June 30, 2024 and 2023
| Convertible Preferred Stock · Common Stock andAdditional Paid-in Capital · Accumulated · AccumulatedOtherComprehensive · TotalStockholders' | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Class A Shares · Amount · Class A Shares · Class B Shares · Amount · Deficit · Income (Loss) · Equity | |||||||||||||
| Balance, December 31, 2023 | — | $— | 218,046,219 | 1,000,000 | $947,745 | $(342,804) | $181 | $605,122 | |||||
| Exercise of stock options | — | — | 37,000 | — | 21 | — | — | 21 | |||||
| Stock-based compensation | — | — | — | — | 5,041 | — | — | 5,041 | |||||
| Net loss | — | — | — | — | — | (14,792) | — | (14,792) | |||||
| Other comprehensive loss | — | — | — | — | — | — | (1,350) | (1,350) | |||||
| Balance, March 31, 2024 | — | — | 218,083,219 | 1,000,000 | 952,807 | (357,596) | (1,169) | 594,042 | |||||
| Issuance of Common Stock for AnHeart acquisition | — | — | 27,646,255 | — | 89,297 | — | — | 89,297 | |||||
| Issuance of convertible preferred stock related to the AnHeart acquisition | 851,202 | 274,938 | — | — | — | — | — | — | |||||
| Issuance of replacement awards related to the AnHeart acquisition | — | — | — | — | 24,818 | — | — | 24,818 | |||||
| Issuance of Common Stock for purchase under the ESPP | — | — | 93,723 | — | 108 | — | — | 108 | |||||
| Issuance of Common Stock for RSUs vested | — | — | 40,342 | — | — | — | — | — | |||||
| Exercise of stock options | — | — | 1,761,190 | — | 1,948 | — | — | 1,948 | |||||
| Stock-based compensation | — | — | — | — | 9,569 | — | — | 9,569 | |||||
| Net loss | — | — | — | — | — | (462,492) | — | (462,492) | |||||
| Currency translation adjustment | — | — | — | — | — | 148 | 148 | ||||||
| Other comprehensive loss | — | — | — | — | — | — | (245) | (245) | |||||
| Balance, June 30, 2024 | 851,202 | $274,938 | 247,624,729 | 1,000,000 | $1,078,547 | $(820,088) | $(1,266) | $257,193 | |||||
| Convertible Preferred Stock · Common Stock andAdditional Paid-in Capital · Accumulated · AccumulatedOtherComprehensive · TotalStockholders' | |||||||||||||
| Class A Shares · Amount · Class A Shares · Class B Shares · Amount · Deficit · Loss · Equity | |||||||||||||
| Balance, December 31, 2022 | — | $— | 217,632,699 | 1,000,000 | $927,604 | $(267,002) | $(5,526) | $655,076 | |||||
| Exercise of stock options | — | — | 171,023 | — | 298 | — | — | 298 | |||||
| Stock-based compensation | — | — | — | — | 4,837 | — | — | 4,837 | |||||
| Net loss | — | — | — | — | — | (21,726) | — | (21,726) | |||||
| Other comprehensive income | — | — | — | — | — | — | 2,588 | 2,588 | |||||
| Balance, March 31, 2023 | — | — | 217,803,722 | 1,000,000 | $932,739 | $(288,728) | $(2,938) | $641,073 | |||||
| Issuance of Common Stock for purchase under the ESPP | — | — | 95,740 | — | 133 | — | — | 133 | |||||
| Stock-based compensation | — | — | — | — | 5,523 | — | — | 5,523 | |||||
| Net loss | — | — | — | — | — | (20,640) | — | (20,640) | |||||
| Other comprehensive loss | — | — | — | — | — | — | (1,457) | (1,457) | |||||
| Balance, June 30, 2023 | — | $— | 217,899,462 | 1,000,000 | $938,395 | $(309,368) | $(4,395) | $624,632 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.